Ver­tex adds a new gene edit­ing part­ner, pay­ing Ob­sid­i­an $75M for con­trol­lable CRISPR sys­tem

Launched by Michael Gilman in 2017, the GV-backed company had been working on a way of controlling cell therapies after they’re administered to a patient, allowing doctors to modulate the potency of CAR-T and other drugs as you might volume on a television set. Wotton wanted to them look beyond cancer, into areas such as gene editing.